Related Experiment Video
Updated: Sep 22, 2025
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.4K
Pharmacology: Non-Insulin Agents
Heather O'Brien1, Catherine Travis2
1Southern Regional Area Health Education Center, 1601 Owen Drive, Fayetteville, NC 28304, USA.
Primary Care
|May 20, 2022
Summary
New diabetes medications, including SGLT2 inhibitors and GLP-1 agonists, offer significant benefits beyond glucose control. These agents provide cardiovascular and renal protection, aiding in weight loss and minimizing hypoglycemia risk.
Area of Science:
- Endocrinology
- Pharmacology
- Cardiovascular Medicine
Background:
- Type 2 diabetes management is evolving beyond traditional therapies.
- Metformin remains a cornerstone, but newer drug classes are gaining prominence.
Purpose of the Study:
- To review the current landscape of type 2 diabetes pharmacotherapy.
- To highlight the benefits and guideline recommendations for newer medication classes.
Main Methods:
- Review of recent clinical guidelines and landmark studies.
- Analysis of efficacy, safety, and long-term outcomes of key diabetes medications.
Main Results:
- Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 agonists demonstrate high efficacy.
- These classes offer significant cardiovascular and renal protective benefits.
- Weight loss and a low risk of hypoglycemia are additional advantages.
Conclusions:
- Newer pharmacotherapies are essential for comprehensive type 2 diabetes management.
- Shared decision-making and patient-centered approaches are crucial for optimizing treatment outcomes.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
279
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
279
01:24Glucagon-like Receptor Agonists
445
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
445
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
288
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
288
01:25Adrenergic Agonists: Indirect-Acting Agents
1.9K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.9K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
315
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
315
01:17Oral Hypoglycemic Agents: Sulfonylureas
357
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
357